KNE — Kane Biotech Balance Sheet
0.000.00%
Last trade - 00:00- CA$6.63m
- CA$7.62m
- CA$2.08m
Annual balance sheet for Kane Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1.01 | 1.15 | 1.1 | 0.749 | 0.359 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.12 | 1.07 | 1.06 | 0.103 | 0.088 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.74 | 2.88 | 3.1 | 3.72 | 1.03 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.163 | 1.44 | 1.25 | 1.07 | 0.929 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 5.04 | 6.13 | 5.62 | 5.68 | 2.49 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.92 | 4.72 | 6.34 | 10.9 | 2.41 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.53 | 10 | 12.1 | 16.2 | 4.12 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -1.49 | -3.89 | -6.52 | -10.6 | -1.63 |
| Total Liabilities & Shareholders' Equity | 5.04 | 6.13 | 5.62 | 5.68 | 2.49 |
| Total Common Shares Outstanding |